A Systematic Review and Meta-Analysis: Volatile Organic Compound Analysis in the Detection of Hepatobiliary and Pancreatic Cancers.
gallbladder cancer
hepatocellular cancer
pancreatic cancer
volatile organic compounds
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Apr 2023
14 Apr 2023
Historique:
received:
28
02
2023
revised:
29
03
2023
accepted:
04
04
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Hepatobiliary cancers are notoriously difficult to detect, frequently leading to diagnosis in later stages of disease when curative treatment is not an option. The currently used biomarkers such as AFP (alpha-fetoprotein) and CA19.9 lack sensitivity and specificity. Hence, there is an unmet need for an alternative biomarker. To evaluate the diagnostic accuracy of volatile organic compounds (VOCs) for the detection of hepatobiliary and pancreatic cancers. A systematic review of VOCs' use in the detection of hepatobiliary and pancreatic cancers was performed. A meta-analysis was performed using the software R. Heterogeneity was explored through meta-regression analysis. A total of 18 studies looking at 2296 patients were evaluated. Pooled sensitivity and specificity of VOCs for the detection of hepatobiliary and pancreatic cancer were 0.79 (95% CI, 0.72-0.85) and 0.81 (97.5% CI, 0.76-0.85), respectively. The area under the curve was 0.86. Meta-regression analysis showed that the sample media used contributed to heterogeneity. Bile-based VOCs showed the highest precision values, although urine and breath are preferred for their feasibility. Volatile organic compounds have the potential to be used as an adjunct tool to aid in the early diagnosis of hepatobiliary cancers.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatobiliary cancers are notoriously difficult to detect, frequently leading to diagnosis in later stages of disease when curative treatment is not an option. The currently used biomarkers such as AFP (alpha-fetoprotein) and CA19.9 lack sensitivity and specificity. Hence, there is an unmet need for an alternative biomarker.
AIM
OBJECTIVE
To evaluate the diagnostic accuracy of volatile organic compounds (VOCs) for the detection of hepatobiliary and pancreatic cancers.
METHODS
METHODS
A systematic review of VOCs' use in the detection of hepatobiliary and pancreatic cancers was performed. A meta-analysis was performed using the software R. Heterogeneity was explored through meta-regression analysis.
RESULTS
RESULTS
A total of 18 studies looking at 2296 patients were evaluated. Pooled sensitivity and specificity of VOCs for the detection of hepatobiliary and pancreatic cancer were 0.79 (95% CI, 0.72-0.85) and 0.81 (97.5% CI, 0.76-0.85), respectively. The area under the curve was 0.86. Meta-regression analysis showed that the sample media used contributed to heterogeneity. Bile-based VOCs showed the highest precision values, although urine and breath are preferred for their feasibility.
CONCLUSIONS
CONCLUSIONS
Volatile organic compounds have the potential to be used as an adjunct tool to aid in the early diagnosis of hepatobiliary cancers.
Identifiants
pubmed: 37190235
pii: cancers15082308
doi: 10.3390/cancers15082308
pmc: PMC10136496
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Molecules. 2021 Apr 22;26(9):
pubmed: 33922256
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Surg Oncol. 2002 May;10(4):153-69
pubmed: 12020670
Scand J Gastroenterol. 2018 Dec;53(12):1569-1574
pubmed: 30621478
Dig Dis Sci. 2015 Jul;60(7):2150-7
pubmed: 25708900
Contemp Oncol (Pozn). 2018;22(3):141-150
pubmed: 30455585
Gastroenterology. 2018 Aug;155(2):431-442.e10
pubmed: 29729258
Clin Exp Gastroenterol. 2019 Aug 14;12:385-390
pubmed: 31616173
Dig Liver Dis. 2020 Jul;52(7):745-752
pubmed: 32402741
Talanta. 2021 Jan 1;221:121604
pubmed: 33076134
Front Oncol. 2022 Nov 21;12:918539
pubmed: 36479080
BMC Cancer. 2018 May 4;18(1):529
pubmed: 29728093
Int J Gastrointest Cancer. 2003;33(1):3-14
pubmed: 12909734
Mol Pharmacol. 2015 Jun;87(6):1013-20
pubmed: 25824487
Sci Rep. 2022 Mar 29;12(1):5326
pubmed: 35351916
Hepatol Commun. 2020 Apr 26;4(7):1041-1055
pubmed: 32626836
Breast J. 2003 May-Jun;9(3):184-91
pubmed: 12752626
J Chromatogr A. 2009 Apr 3;1216(14):2749-56
pubmed: 19036381
Front Oncol. 2022 Mar 30;12:858639
pubmed: 35433420
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30
pubmed: 15817806
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):571-9
pubmed: 23542803
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Br J Cancer. 2011 May 10;104(10):1649-55
pubmed: 21505455
Cancers (Basel). 2020 Dec 07;12(12):
pubmed: 33297469
Ann Surg. 2019 May;269(5):903-910
pubmed: 29194085
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Gut. 2018 Jan;67(1):128-137
pubmed: 28108468
Thorax. 2021 May;76(5):514-521
pubmed: 33414240
Hepatology. 2006 Jun;43(6):1303-10
pubmed: 16729298
Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):53-64
pubmed: 31811279
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):698-710
pubmed: 32135127
PLoS One. 2020 Jul 31;15(7):e0236591
pubmed: 32735600
J Dig Dis. 2021 Feb;22(2):62-71
pubmed: 33369216
Aliment Pharmacol Ther. 2021 Jul;54(1):14-23
pubmed: 34004036
Br J Cancer. 2010 Aug 10;103(4):542-51
pubmed: 20648015
Analyst. 2015 Oct 21;140(20):6775-81
pubmed: 26205889
Clin Chim Acta. 2008 Sep;395(1-2):19-26
pubmed: 18538135
J Breath Res. 2017 Nov 29;12(1):016006
pubmed: 28439048
Antioxid Redox Signal. 2000 Winter;2(4):903-17
pubmed: 11213491
Endoscopy. 2021 Jul;53(7):732-736
pubmed: 32894868
J Natl Compr Canc Netw. 2021 May 1;19(5):541-565
pubmed: 34030131
Br J Surg. 2018 Oct;105(11):1493-1500
pubmed: 30019405
Biomark Med. 2016 Jun;10(6):577-86
pubmed: 27171159
Proc Natl Acad Sci U S A. 1971 Oct;68(10):2374-6
pubmed: 5289873
Nanomedicine. 2013 Jan;9(1):15-21
pubmed: 22967910
J Adv Pract Oncol. 2022 Apr;13(3):320-323
pubmed: 35663158
Gastrointest Endosc. 2015 Apr;81(4):943-9.e1
pubmed: 25500329
Chem Soc Rev. 2014 Mar 7;43(5):1423-49
pubmed: 24305596
Anticancer Res. 2019 Jan;39(1):73-79
pubmed: 30591442
Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2247-53
pubmed: 20826831
JAMA Oncol. 2019 Jan 1;5(1):e182815
pubmed: 30128487
J Breath Res. 2014 Sep;8(3):034001
pubmed: 24946087
Int J Cancer. 2010 Jun 1;126(11):2663-70
pubmed: 19839051
Br J Cancer. 1989 Jan;59(1):6-11
pubmed: 2547414
J Clin Oncol. 2009 Mar 20;27(9):1485-91
pubmed: 19224838
Lung Cancer. 2010 Feb;67(2):227-31
pubmed: 19409642
Clin Chim Acta. 2017 May;468:98-104
pubmed: 28215548
J Breath Res. 2010 Jun;4(2):026003
pubmed: 21383471
EBioMedicine. 2020 Apr;54:102725
pubmed: 32330874
Expert Rev Mol Diagn. 2020 May;20(5):489-496
pubmed: 32130868
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Gastroenterology. 2018 Feb;154(3):485-487.e1
pubmed: 29129714
Respir Res. 2005 Jul 14;6:71
pubmed: 16018807
J Biochem. 2011 Sep;150(3):257-66
pubmed: 21771869
Chem Rev. 2012 Nov 14;112(11):5949-66
pubmed: 22991938
World J Gastroenterol. 2015 Nov 21;21(43):12211-7
pubmed: 26604631
J Breath Res. 2021 Apr 21;15(3):
pubmed: 33761469